Conflict of interest: All authors have no conflicts of interest to disclose.
Effect of home mechanical in-exsufflation on hospitalisation and life-style in neuromuscular disease: A pilot study
Article first published online: 26 FEB 2013
© 2013 The Authors. Journal of Paediatrics and Child Health © 2013 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
Journal of Paediatrics and Child Health
Volume 49, Issue 3, pages 233–237, March 2013
How to Cite
Moran, F. C., Spittle, A., Delany, C., Robertson, C. F. and Massie, J. (2013), Effect of home mechanical in-exsufflation on hospitalisation and life-style in neuromuscular disease: A pilot study. Journal of Paediatrics and Child Health, 49: 233–237. doi: 10.1111/jpc.12111
This study was performed at The Royal Children's Hospital, Melbourne, Australia.
No funding was received for this study.
- Issue published online: 10 MAR 2013
- Article first published online: 26 FEB 2013
- Manuscript Accepted: 26 JUL 2012
- muscular atrophy;
- muscular dystrophy;
- neuromuscular diseases;
- quality of life
Mechanical in-exsufflation (MI-E) augments the weakened cough of patients with neuromuscular disease (NMD), clearing secretions and overcoming atelectasis. Little has been published on the impact of MI-E alone on rates of hospitalisation and quality of life (QOL). The aim of this study was to assess the impact of home MI-E on hospital admissions and life-style in children with NMD.
A retrospective chart review was performed on children using MI-E, including data on the number of admissions to hospital, length of stay and hours of ventilation. A parental survey was used to gather information on the impact of MI-E on life-style for the child and family.
Ten children with NMD (seven spinal muscular atrophy, two Duchenne muscular dystrophy and one centronuclear myopathy) using MI-E at home were identified. MI-E use commenced at mean age of 8.5 years (range 1.1–16.9) with 1.4 years of use (range 0.3–3.8). MI-E pressures ranged from +/−30 to 40 cmH2O with no complications reported. There was a significant reduction in hospital days at 6 (P = 0.036) and 12 (P = 0.028) months following commencement of home MI-E compared with the same period preceding MI-E use. The survey highlighted positive benefits of MI-E use, in particular the ability to treat many pulmonary exacerbations at home.
Home MI-E use by children with NMD can reduce hospitalisation and benefit families by maintaining their child at home.